title: Autologous cell therapies: the importance of regulatory oversight.
abstract: Promising new medical technologies and approaches to treatment offer the potential to substantially improve the lives of patients who need help, and in some cases transform the way medicine is practiced. In recent years, the biotechnology industry has generated many examples of new approaches that are having a profound impact on medical care, including protein and peptide therapeutics, monoclonal antibodies and molecular diagnostics.
authors.affiliation: Athersys, Inc., (NASDAQ: ATHX), 3201 Carnegie Avenue, Cleveland 44115-2653, OH, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Werner
authors.forename: Tim
authors.initials: T
authors.lastname: Mayleben
authors.forename: Gil
authors.initials: G
authors.lastname: Van Bokkelen
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D005843:Geography; D033161:Government Regulation; D006801:Humans; D011634:Public Health / Q000331:legislation & jurisprudence; D014182:Transplantation, Autologous / Q000331:legislation & jurisprudence; D014481:United States; D014486:United States Food and Drug Administration